Biomea Fusion is issuing 11,195,121 shares and 1,000,000 pre-funded warrants under an October 6, 2025 prospectus supplement, for $24,999,898 before discounts. Jefferies is book-running manager and H.C. Wainwright & Co., LLC is lead manager.
Latest Biomea Fusion news
We have not published a story on Biomea Fusion yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $34.8 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Biomea Fusion
Has Biomea Fusion raised money recently?
Our latest story on this, dated Oct 6, 2025: "Biomea Fusion prices $24,999,898 offering of stock and warrants at $2.05". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Biomea Fusion?
Biomea Fusion, Inc. trades under the ticker BMEA on NASDAQ.
Where is Biomea Fusion listed?
Biomea Fusion, Inc. is listed on NASDAQ.
What is the SEC CIK of Biomea Fusion?
The SEC Central Index Key (CIK) for Biomea Fusion, Inc. is 1840439. Its filings are on SEC EDGAR.
How many shares does Biomea Fusion have outstanding?
72,483,852 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Biomea Fusion listed under?
Our directory records Biomea Fusion, Inc. under United States.
What does Biomea Fusion do?
Our directory classifies Biomea Fusion, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Biomea Fusion?
The ISIN recorded for Biomea Fusion, Inc. is US09077A1060.
Does aibio.space cover Biomea Fusion?
aibio.space lists Biomea Fusion, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Biomea Fusion incorporated?
SEC records list its state or country of incorporation as DE.
Is Biomea Fusion profitable?
Biomea Fusion, Inc. reported a net loss of $61.8 million for the fiscal year ended Dec 31, 2025, and used $70.4 million of cash in operations, per its annual report to the SEC.
How much does Biomea Fusion spend on research and development?
$62.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Biomea Fusion have?
$34.8 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Biomea Fusion (BMEA) stock news?
Our latest story on Biomea Fusion, dated Oct 6, 2025: "Biomea Fusion prices $24,999,898 offering of stock and warrants at $2.05". Biomea Fusion is issuing 11,195,121 shares and 1,000,000 pre-funded warrants under an October 6, 2025 prospectus supplement, for $24,999,898 before discounts. Jefferies is book-running manager and H.C. Wainwright & Co., LLC is lead manager. Source.
How long will Biomea Fusion's cash last?
From our story of Oct 6, 2025: Without the new money, the company says its cash would fund planned operations into the second half of 2026. Source.
Investor discussion: Biomea Fusion
Members talk about Biomea Fusion (BMEA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Biomea Fusion, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,7.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:BMEA on TradingView.
SEC filings and registration
SEC name
Biomea Fusion, Inc.
CIK
1840439
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
BMEA (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
1599 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
Phone
(650) 980-9099
Shares outstanding
72,483,852 as of 2026-07-31 (10-Q filed 2026-08-05)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Biomea Fusion, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BMEA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio